^
Association details:
| Biomarker: | KRAS G12D |
|---|---|
| Cancer: | Gallbladder Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The Misaligned Clinical Course Due to a Missed Mismatch Repair–Deficient Gallbladder Carcinoma
Published date:
10/14/2020
Excerpt:
We introduce an initially missed D-MMR gallbladder carcinoma in a 50-year-old woman... immunostaining uncovered loss of MSH6 and MSH2 but retained MLH1 and PMS2 in the tumor (Figure 292). Molecular testing confirmed D-MMR and further detected KRAS G12D mutation. These findings led to pembrolizumab-based management and after 6 cycles, imaging studies confirmed the residual tumor had disappeared. The patient remains disease free 1 year later.
DOI:
https://doi.org/10.5858/arpa.2020-0991-AB
